for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck KGaA

MRCG.DE

Latest Trade

106.00EUR

Change

-0.30(-0.28%)

Volume

373,646

Today's Range

105.45

 - 

107.05

52 Week Range

85.84

 - 

107.35

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
106.30
Open
106.30
Volume
373,646
3M AVG Volume
9.78
Today's High
107.05
Today's Low
105.45
52 Week High
107.35
52 Week Low
85.84
Shares Out (MIL)
434.78
Market Cap (MIL)
13,699.68
Forward P/E
19.22
Dividend (Yield %)
1.18

Next Event

Q3 2019 Merck KGaA Earnings Release

Latest Developments

More

Progyny Says Merck Ventures Owns 6.6% Stake In Co Prior To IPO

Merck KGaA Says Chinese Regulator Approves Cancer Treatment Erbitux

Merck KGaA Wins CHMP Positive Opinion For Rebif Label Amendment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck KGaA

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Performance Materials business provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.

Industry

Major Drugs

Contact Info

Frankfurter Str. 250

+49.6151.720

https://www.merckgroup.com/

Executive Leadership

Stefan Oschmann

Chairman of Executive Board and Chief Executive Officer

Wolfgang Buechele

Independent Chairman of the Supervisory Board

Michael Fletterich

Independent Vice Chairman of the Supervisory Board, Employee Representative

Marcus Kuhnert

Member of the Executive Board, Chief Financial Officer

Udit Batra

Chief Executive Officer Life Science, Member of the Executive Board

Key Stats

2.43 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

15.0K

2017

15.3K

2018

14.8K

2019(E)

15.6K
EPS (EUR)

2016

6.210

2017

6.160

2018

5.100

2019(E)

5.508
Price To Earnings (TTM)
41.29
Price To Sales (TTM)
0.89
Price To Book (MRQ)
2.69
Price To Cash Flow (TTM)
4.79
Total Debt To Equity (MRQ)
65.13
LT Debt To Equity (MRQ)
37.02
Return on Investment (TTM)
4.01
Return on Equity (TTM)
3.01

Latest News

Latest News

Merck KGaA completes acquisition of Versum Materials

Germany's Merck KGaA <MRCG.DE> said on Monday it had completed its acquisition of Versum Materials <VSM.N> , adding that it expected Versum to contribute around 270 million euros ($296.76 million) to group revenues by the end of the year.

Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation.

Merck KGaA's profit bolstered by lab supplies, drug milestone payments

Germany's Merck KGaA <MRCG.DE> posted a gain in quarterly earnings that was slightly higher than market expectations thanks to strong sales growth at its lab supplies unit and milestone payments from drug development partners.

Merck KGaA's Q2 profit bolstered by drug milestone payments

Germany's Merck KGaA posted a gain in quarterly earnings that was slightly higher than market expectations, driven by drug development milestone payments from partners Pfizer and GlaxoSmithKline .

Roche brags about faster Ocrevus sales after rival MS drug launches

Roche <ROG.S> took a swipe at rival drugmakers on Thursday saying their attempts to muscle in to the multiple sclerosis market had only boosted sales of its own product.

Merck KGaA sees currencies supporting 2019 outlook

Germany's Merck KGaA, which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth this year.

Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals

Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris.

Merck KGaA agrees $6.5 bln takeover of Versum

Germany's Merck KGaA said it signed a takeover agreement with target Versum Materials for a price of $53 per share after Versum walked away from a prior merger agreement with rival Entegris .

Merck KGaA wins Versum's support for sweetened $6.5 billion offer

Merck KGaA won the backing of Versum's board for a sweetened $6.5 billion takeover proposal, overturning an agreed merger with rival Entegris as it bets on a recovery in electronic materials markets.

Merck KGaA raises offer for Versum Materials to $53 per share

Versum Materials Inc said on Monday that Merck KGaA had raised its offer for the company to $53 per share from $48.

UPDATE 1-German stocks - Factors to watch on April 1

The following are some of the factors that may move German stocks on Monday:

Versum opens books, begins to warm to rival suitor Merck KGaA

Versum Materials Inc has opened its books to suitor Merck KGaA, saying the German group's unsolicited $5.9 billion (£4.54 billion) offer might be sweetened and could edge out an agreed merger with Entegris.

Merck KGaA welcomes Versum's decision to talk, keeps tender going

Merck KGaA on Friday welcomed Versum Materials to the negotiation table after the takeover target said it was willing to hold talks over Merck's unsolicited offer.

Merck KGaA welcomes Versum's decision to talk, keeps tender going

Merck KGaA on Friday welcomed Versum Materials to the negotiation table after the takeover target said it was willing to hold talks over Merck's unsolicited offer.

CORRECTED-UPDATE 1-Versum urges shareholders to reject Merck KGaA hostile bid

Versum Materials Inc on Friday urged its shareholders to reject a hostile bid from Merck KGaA , but said it would engage with the German pharma group to determine if the offer is superior to its agreed merger with rival Entegris.

Versum urges shareholders to reject Merck KGaA hostile bid

Versum Materials Inc on Friday urged its shareholders to reject a hostile bid from Merck KGaA , but said it would engage with the German pharma group to determine if the offer is superior to its agreed merger with rival Entegris.

BRIEF-Merck KGaA - 150 Mln Eur Investement In Aubonne Site

* €150 MILLION INVESTMENT OVER THE 2019-2023 PERIOD IN MANUFACTURING SITE AT AUBONNE, SWITZERLAND

Merck KGaA goes hostile in $5.9 billion Versum takeover battle

German pharma group Merck KGaA launched a hostile $5.9 billion (£4.5 billion) all-cash takeover offer for Versum Materials on Tuesday to boost its presence in the semiconductor materials market and sideline a rival bidder.

Merck KGaA makes takeover offer for Versum to shareholders

Germany's Merck KGaA on Tuesday said it made a full takeover bid to shareholders of Versum Materials for $48 per share, after a previous deal proposal for the same price was rejected by the U.S. target's management.

Merck KGaA calls on Versum investors to vote down Entegris merger

Merck KGaA on Tuesday reiterated its recommendation to shareholders of its takeover target Versum to reject the electronic materials maker's planned merger with peer Entegris.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up